【摘要】：目的系統(tǒng)評(píng)價(jià)吸入性糖皮質(zhì)激素預(yù)防早產(chǎn)兒慢性肺疾病(CLD)的有效性和安全性。方法計(jì)算機(jī)檢索Pub Med、EMBASE、CENTRAL、the ISI Web of Knowledge Databases、CBM、CNKI和VIP、Wan Fang Data,檢索時(shí)限均為建庫(kù)至2016年10月,搜集所有研究吸入性糖皮質(zhì)激素防治早產(chǎn)兒CLD的療效和安全性的隨機(jī)對(duì)照試驗(yàn)(RCT),并進(jìn)行RCT的篩選、資料提取和質(zhì)量評(píng)價(jià),應(yīng)用Rev Man 5.3軟件進(jìn)行meta分析。結(jié)果共納入12篇RCT,2 051例早產(chǎn)兒。與對(duì)照組比較,28天組吸入糖皮質(zhì)激素組,以及吸入布地奈德亞組、倍氯米松亞組和氟替卡松亞組,CLD發(fā)生率的差異無(wú)統(tǒng)計(jì)學(xué)意義(P均0.05)。與對(duì)照組比較,校正胎齡36周組吸入糖皮質(zhì)激素組(RR=0.70,95%CI:0.61~0.80)、霧化吸入亞組(RR=0.74,95%CI:0.63~0.87)、氣管內(nèi)給藥亞組(RR=0.57,95%CI:0.43~0.76)以及布地奈德亞組(RR=0.67;95%CI:0.57~0.78)和氟替卡松亞組(RR=0.58,95%CI:0.36~0.94),CLD發(fā)生率的差異有統(tǒng)計(jì)學(xué)意義(P均0.05);而倍氯米松組CLD發(fā)生率與對(duì)照組差異無(wú)統(tǒng)計(jì)學(xué)意義(P=0.90);總的病死率差異無(wú)統(tǒng)計(jì)學(xué)意義(P=0.55);霧化吸入亞組和氣管內(nèi)給藥亞組以及布地奈德亞組、倍氯米松亞組和氟替卡松亞組病死率與對(duì)照組比較差異無(wú)統(tǒng)計(jì)學(xué)意義(P均0.05)。結(jié)論預(yù)防性使用吸入性糖皮質(zhì)激素能有效降低早產(chǎn)兒CLD的發(fā)病率,但對(duì)病死率無(wú)影響,與給藥方式和給藥類型無(wú)顯著相關(guān)性。同時(shí)推薦以校正胎齡36周為結(jié)局指標(biāo)觀察點(diǎn),但相關(guān)研究數(shù)量有限,且缺乏長(zhǎng)期隨訪結(jié)果,因此吸入性糖皮質(zhì)激素的作用及遠(yuǎn)期并發(fā)癥,仍需大量的臨床研究來(lái)評(píng)估,建議臨床謹(jǐn)慎使用。
[Abstract]:Objective to evaluate the efficacy and safety of inhaled glucocorticoid in the prevention of (CLD) in premature infants with chronic lung disease. Methods both Pub Med,EMBASE,CENTRAL,the ISI Web of Knowledge Databases,CBM,CNKI and VIP,Wan Fang Data, were searched by computer until October 2016. All randomized controlled trials (RCT),) to study the efficacy and safety of inhaled glucocorticoid in preventing and treating CLD in premature infants were collected and RCT screening was performed. Data extraction and quality evaluation, meta analysis using Rev Man 5.3 software. Results A total of 12 RCT,2 cases were included in this study. Compared with the control group, there was no significant difference in the incidence of CLD in the 28 day inhaled glucocorticoid group, the inhaled budesonide subgroup, beclomethasone subgroup and fluticasone subgroup (P0. 05). Compared with the control group, The incidence of corticosteroid inhalation (RR=0.70,95%CI:0.61~0.80), nebulized inhaled subgroup (RR=0.74,95%CI:0.63~0.87), intratracheal administration subgroup (RR=0.57,95%CI:0.43~0.76), budesonide subgroup (RR=0.67;95%CI:0.57~0.78) and fluticasone subgroup (RR=0.58,95%CI:0.36~0.94), CLD) in 36 weeks of corrected gestational age group were significantly different, whereas the incidence of CLD in beclomethasone group was significantly higher than that in beclomethasone group (P < 0. 05). There was no significant difference between the incidence rate and the control group (P < 0.90), there was no significant difference in the overall mortality rate (P < 0.55), the nebulization subgroup, the intratracheal administration subgroup and the budesonide subgroup were not significantly different from those in the control group. There was no significant difference in mortality between betamethasone subgroup and fluticasone subgroup (P 0.05). Conclusion prophylactic use of inhaled glucocorticoids can effectively reduce the incidence of CLD in premature infants, but has no effect on the mortality, and has no significant correlation with the administration mode and type of administration. At the same time, 36 weeks of corrected gestational age is recommended as the observation point of outcome, but the number of related studies is limited and there is no long-term follow-up results. Therefore, the role of inhaled glucocorticoids and long-term complications still need a large number of clinical studies to evaluate. Clinical caution is recommended.
【作者單位】： 西南醫(yī)科大學(xué)附屬醫(yī)院新生兒科;
【分類號(hào)】：R722.6

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 毛一馨;早期使用地塞米松——嘗試防止慢性肺疾病[J];國(guó)外醫(yī)學(xué).婦產(chǎn)科學(xué)分冊(cè);2001年06期

2 富建華,薛辛東;慢性肺疾病早產(chǎn)鼠肺組織轉(zhuǎn)化生長(zhǎng)因子β_1基因及蛋白表達(dá)的動(dòng)態(tài)變化(英文)[J];中國(guó)當(dāng)代兒科雜志;2005年03期

3 禹定樂;劉恩梅;;病毒感染與常見兒童慢性肺疾病相關(guān)性研究進(jìn)展[J];兒科藥學(xué)雜志;2012年07期

4 富建華,薛辛東;慢性肺疾病早產(chǎn)鼠轉(zhuǎn)化生長(zhǎng)因子β_1基因和蛋白動(dòng)態(tài)表達(dá)及其對(duì)肺發(fā)育的抑制作用[J];中華兒科雜志;2005年06期

5 尚云曉;;慢性肺疾病及其診斷思路[J];中國(guó)實(shí)用兒科雜志;2007年04期

6 王穎;支氣管肺發(fā)育不良(新生兒慢性肺疾病)的診斷與治療[J];實(shí)用醫(yī)學(xué)雜志;2005年17期

7 張謙慎;常立文;容志惠;;早產(chǎn)兒慢性肺疾病支氣管肺泡灌洗液中細(xì)胞外基質(zhì)的變化[J];中國(guó)實(shí)用兒科雜志;2006年09期

8 全裕鳳;鄭明慈;;早產(chǎn)兒慢性肺疾病的防治現(xiàn)狀及展望[J];華夏醫(yī)學(xué);2009年05期

9 羅英;唐麗君;黃為民;;慢性肺疾病患兒外周血細(xì)胞因子的改變[J];中國(guó)當(dāng)代兒科雜志;2010年11期

10 王愛武;;經(jīng)鼻持續(xù)氣道正壓通氣在早產(chǎn)兒呼吸窘迫綜合征中應(yīng)用探討[J];中國(guó)臨床新醫(yī)學(xué);2013年05期

相關(guān)會(huì)議論文 前2條

1 常立文;李文斌;陳曄;張煉;盧紅艷;;新生兒慢性肺疾病的診治探討(附60例病例分析)[A];中華醫(yī)學(xué)會(huì)第十四次全國(guó)兒科學(xué)術(shù)會(huì)議論文匯編[C];2006年

2 高喜容;吳運(yùn)芹;李磊;黃玫;劉暉;;早產(chǎn)兒慢性肺疾病臨床分析[A];中華醫(yī)學(xué)會(huì)第十四次全國(guó)兒科學(xué)術(shù)會(huì)議論文匯編[C];2006年

相關(guān)碩士學(xué)位論文 前3條

1 張杰;高氧致早產(chǎn)鼠慢性肺疾病中血小板源性生長(zhǎng)因子及受體變化的研究[D];中國(guó)醫(yī)科大學(xué);2004年

2 袁杰;高氧致慢性肺疾病早產(chǎn)鼠肺組織Foxa_2的表達(dá)及意義[D];瀘州醫(yī)學(xué)院;2010年

3 高英;高氧致慢性肺疾病早產(chǎn)鼠肺組織CDK4、P21的表達(dá)及意義[D];中國(guó)醫(yī)科大學(xué);2006年

，

本文編號(hào)：2284072